Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-Blind, placebo-controlled, parallel-group, multicenter study to determine the safety and efficacy of natalizumab, when added to Avonex (interferon beta-1a), in subjects with relapsing-remitting multiple sclerosis

Next Previous
X
Search
Trial Profile

A randomized, double-Blind, placebo-controlled, parallel-group, multicenter study to determine the safety and efficacy of natalizumab, when added to Avonex (interferon beta-1a), in subjects with relapsing-remitting multiple sclerosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Natalizumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms SENTINEL
  • Sponsors Biogen

    • Most Recent Events

    • 01 Oct 2023 Results from pooled analysis from NCT00027300, NCT00030966 associations association of age and inflammatory disease activity published in the Journal of Neurology, Neurosurgery and Psychiatry.
    • 12 Oct 2018 Results from ADVANCE, CHAMPS, MSCRG and SENTINEL assessing Serum neurofilament light, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 17 Sep 2016 Results of this and other four trials assessing relationship of natalizumab exposure and MRI response presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top